New study shows remdesivir works in coronavirus therapy, but it might not be enough

$%name New study shows remdesivir works in coronavirus therapy, but it might not be enough by Authcom, Nova Scotia\s Internet and Computing Solutions Provider in Kentville, Annapolis Valley$

Data from a new coronavirus drug trial shows that a 5-day course of remdesivir therapy is more effective than standard care, and works just as well as a 10-day course.
The results only apply to a specific set of COVID-19 patients, namely people who developed a moderate case, which included pneumonia without reduced oxygen levels.
The new Phase 3 SIMPLE remdesivir study indirectly suggests the drug won’t work in severe cases, and it will not affect COVID-19 mortality rates. The results are in line with a previously published trial.

The novel coronavirus still has no cure, but doctors have devised plenty of therapies that have shown promise and are in various stages of testing. One of them is remdesivir, the drug that received Dr. Anthony Fauci’s endorsement in late April. We learned at the time that remdesivir can speed up recovery, reducing it down from 15 days with other types of care to 11 days. Fauci said at the time that the drug didn’t affect mortality rates and that remdesivir may have to be combined with different medicine to improve COVID-19 therapy.

The study was published a few weeks later, further confirming these findings, and making it clear that remdesivir isn’t the miracle COVID-19 drug we’ve been waiting for. The maker of remdesivir on Monday published an additional study on Monday that says that remdesivir works in COVID-19 therapies. However, Gilead’s Phase 3 study assessed the length of treatment, and its conclusions may only apply to a certain subset of patients.

Continue reading…

Today’s Top Deals

Trending Right Now:

New study shows remdesivir works in coronavirus therapy, but it might not be enough originally appeared on BGR.com on Mon, 1 Jun 2020 at 19:05:57 EDT. Please see our terms for use of feeds.